Blood test may predict liver cancer treatment success
NCT ID NCT07303712
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a blood test (liquid biopsy) can predict how well liver cancer responds to a type of internal radiation called Y90 radioembolization. Researchers will take blood samples from 12 adults with liver cancer before and after treatment to look for tumor cells and DNA. The goal is to see if early changes in these markers can forecast treatment success, potentially guiding future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VA Palo Alto Health Care System
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'No-Touch' microwave technique match surgery for liver tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- AI-Powered surveillance may outsmart liver cancer recurrence
- Blood markers may forecast liver cancer treatment success
- Can a diabetes drug help fight liver cancer? a trial puts it to the test
- Can a triple therapy shrink untreatable liver tumors?